|drug2514||Placebo oral tablet Wiki||0.17|
There is one clinical trial.
The Study is Designed as A Combined Phase I Double-Blind Randomized Placebo controlled/IIa, Randomized, Double-blind, Placebo controlled, Multi-center Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001 in Subjects Infected with SARS-CoV-2. Part A: To determine the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) profiles of MRG-001 in asymptomatic SARS-CoV-2 infected subjects. Part B: To determine the safety and efficacy profile of MRG-001 in patients with moderate-to-severe COVID-19. A total of 132 subjects will be enrolled and randomized in 1:1 ratio to receive MRG-001 or placebo. All subjects will be treated with the best available treatment. The follow-up period is up to 28 days.
Description: Change from baseline in the proportion of subjects experiencing any treatment emergent adverse event (TEAE) associated with MRG-001 to Day 12.Measure: Phase Ib Time: 12 days
Description: Time to clinical improvement from randomization to Day 28 by at least 2 points on the 8-point ordinal scale of WHO clinical improvement scale (1 = discharged; 8 = death).Measure: Phase IIa Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports